Puerarin-loaded hyaluronic acid self-assembled nanoparticles ameliorate hyperuricemic nephropathy by modulating lipid peroxidation and macrophage polarization
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Gout, Hyperuricemia, Uric Acid · Chronic Kidney Disease and Diabetes · Kidney Stones and Urolithiasis Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Hyperuricemia, urate deposition and the association with hypertension10.1185/03007995.2015.1087981 ↗
2. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population
3. Update on gout: pathophysiology and potential treatments10.1007/s11916-007-0231-3 ↗
4. Dioscin ameliorates hyperuricemia-induced atherosclerosis by modulating of cholesterol metabolism through FXR-signaling pathway10.3390/nu14091983 ↗
5. Hyperuricemia and diabetes mellitus when occurred together have higher risks than alone on all-cause mortality and end-stage renal disease in patients with chronic kidney disease10.1186/s12882-022-02755-1 ↗
6. Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder10.1186/s12888-018-1952-z ↗
7. Uric acid and oxidative stress10.2174/138161205774913255 ↗
8. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system10.1097/HJH.0b013e3282f240bf ↗
9. Pharmacology of oxidative stress: translational opportunities10.1111/bph.13795 ↗
10. Free radicals, reactive oxygen species, oxidative stress and its classification10.1016/j.cbi.2014.10.016 ↗
11. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension10.1155/2015/535686 ↗
12. A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress10.1016/j.ejphar.2022.175157 ↗
13. Bioactive nanoenzyme reverses oxidative damage and endoplasmic reticulum stress in neurons under ischemic stroke10.1021/acsnano.1c07205 ↗
14. Protective effect of crocin on peroxidation-induced oxidative stress and apoptosis in IPEC-J2 cells10.1002/tox.24216 ↗
15. Deciphering the interaction of puerarin with cancer macromolecules: Anin silicoinvestigation10.1080/07391102.2020.1819425 ↗
16. Antioxidant food components for the prevention and treatment of cardiovascular diseases: effects, mechanisms, and clinical studies
17. The antihyperuricemic and nephroprotective effect of puerarin by reducing uric acid level and exerting anti-inflammatory activity10.1002/efd2.70005 ↗
18. Tissue distribution of puerarin and its conjugated metabolites in rats assessed by liquid chromatography-tandem mass spectrometry10.1016/j.phymed.2008.09.004 ↗
19. Promising polyphenols in parkinson's disease therapeutics10.1007/s11064-020-03058-3 ↗
20. Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system10.3109/03639041003610799 ↗
21. Formulation and pharmacokinetics evaluation of puerarin nanocrystals for intravenous delivery10.1166/jnn.2012.6436 ↗
22. Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery10.1016/j.ijpharm.2012.02.013 ↗
23. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration10.1016/j.ijpharm.2011.02.064 ↗
24. Nanoparticle-based drug delivery system-A target strategy for osteoarthritis treatment10.1155/2021/4064983 ↗
25. Carrier-free nanoparticles-new strategy of improving druggability of natural products10.1186/s12951-025-03146-y ↗
26. Co-delivery of doxorubicin and curcumin via cRGD-peptide modified PEG-PLA self-assembly nanomicelles for lung cancer therapy10.1016/j.cclet.2021.11.076 ↗
27. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives10.1016/j.apsb.2021.05.002 ↗
28. Hyaluronic acid and albumin based nanoparticles for drug delivery10.1016/j.jconrel.2021.01.033 ↗
29. Injectable hyaluronic acid-based hydrogel niches to create localized and time-controlled therapy delivery
30. Sustained therapeutic effects of self-assembled hyaluronic acid nanoparticles loaded with α-Ketoglutarate in various osteoarthritis stages10.1016/j.biomaterials.2024.122845 ↗
31. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: Beyond CD44-mediated drug delivery10.1002/adma.201803549 ↗
32. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy10.1038/ki.2014.87 ↗
33. CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy10.1097/01.ASN.0000115703.30835.96 ↗
34. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells10.18632/oncotarget.8926 ↗
35. CD44-targeted hyaluronic acid-curcumin prodrug protects renal tubular epithelial cell survival from oxidative stress damage10.1016/j.carbpol.2018.04.011 ↗
36. Self-assembled hyaluronic acid nanoparticles for the topical treatment of inflammatory skin diseases: Beyond drug carriers10.1016/j.jconrel.2023.12.026 ↗
37. Modulation of alveolar macrophage and mitochondrial fitness by medicinal plant-derived nanovesicles to mitigate acute lung injury and viral pneumonia10.1186/s12951-024-02473-w ↗
38. Thymus quinquecostatus Celak. ameliorates cerebral ischemia-reperfusion injury via dual antioxidant actions: Activating Keap1/Nrf2/HO-1 signaling pathway and directly scavenging ROS10.1016/j.phymed.2021.153673 ↗
39. p38 MAPK: stress responses from molecular mechanisms to therapeutics10.1016/j.molmed.2009.06.005 ↗
40. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice10.1038/ncomms14181 ↗
41. Intranasal delivery of pure nanodrug loaded liposomes for alzheimer's disease treatment by efficiently regulating microglial polarization10.1002/smll.202405781 ↗
42. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis10.1016/j.carbpol.2023.121018 ↗
43. M1/M2 re-polarization of kaempferol biomimetic NPs in anti-inflammatory therapy of atherosclerosis10.1016/j.jconrel.2022.12.041 ↗
44. The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis10.3389/fphar.2023.1335094 ↗
45. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization10.1016/j.intimp.2020.106969 ↗
46. Puerarin modulates the P62-Keap1-NRF2 pathway and enhances CA7 function to inhibit ferroptosis in ethanol-induced gastric mucosal injury10.1016/j.fbio.2025.106127 ↗
47. Puerarin alleviates atherosclerosis via the inhibition of Prevotella copri and its trimethylamine production10.1136/gutjnl-2024-331880 ↗
48. Melatonin counteracts oxidative damage in lens by regulation of Nrf2 and NLRP3 inflammasome activity10.1016/j.exer.2021.108912 ↗
49. Linarin attenuates hyperuricemic nephropathy by modulating Nrf2/Keap1 and TLR4/NF-κB signaling pathways Linarin attenuates hyperuricemic nephropathy10.1016/j.phymed.2025.156440 ↗
50. Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury10.1016/j.ejmech.2021.113599 ↗
51. Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway10.1080/21655979.2020.1868733 ↗
52. Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment
53. Lithospermic acid etched ZIF-8 nanoparticles delays osteoarthritis progression by inhibiting inflammatory signaling pathways and rescuing mitochondrial damage